Literature DB >> 32409869

Prognostic value of plasma fibrinogen and D-dimer levels in patients with surgically resected non-small cell lung cancer.

Shuta Ohara1, Kenichi Suda2, Kenji Tomizawa1, Toshiki Takemoto1, Toshio Fujino1, Akira Hamada1, Takamasa Koga1, Masaya Nishino1, Masato Chiba1, Katsuaki Sato1, Masaki Shimoji1, Junichi Soh1, Tetsuya Mitsudomi1.   

Abstract

PURPOSE: A high plasma level of either fibrinogen or D-dimer has been shown to correlate with a poor prognosis in patients with surgically resected non-small-cell lung cancer (NSCLC). The present study aimed to identify whether or not both markers combined had a superior prognostic value to either alone.
METHODS: Of the 1344 patients who underwent surgical resection for NSCLC at our institution between January 2007 and December 2016, 1065 had preoperative plasma fibrinogen and D-dimer data available and were included in the analysis.
RESULTS: The recurrence-free survival (RFS) and overall survival (OS) rates were similar for patients with high plasma levels of either or both fibrinogen (> 4.0 g/L) or D-dimer (> 1.0 μg/mL); therefore, these three groups were combined for a further analysis into a single group with high plasma levels of either or both proteins. The high-level group had significantly lower 5-year RFS (53% vs. 68%, p < 0.001) and 5-year OS (65% vs. 80%, p < 0.001) rates than patients with normal plasma levels of fibrinogen and D-dimer (control group).
CONCLUSIONS: Our results suggest that preoperative tests for both plasma fibrinogen and D-dimer are necessary to identify patients with surgically resected NSCLC likely to have a poor RFS and OS.

Entities:  

Keywords:  Non-small cell lung cancer; Plasma D-dimer; Plasma fibrinogen; Prognostic factors

Year:  2020        PMID: 32409869     DOI: 10.1007/s00595-020-02019-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  5 in total

1.  Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.

Authors:  Masashi Iwasaki; Shunta Ishihara; Satoru Okada; Reona Shimegi; Masanori Shimomura; Masayoshi Inoue
Journal:  Ann Surg Oncol       Date:  2022-06-02       Impact factor: 4.339

Review 2.  Coagulation parameters in lung cancer patients: A systematic review and meta-analysis.

Authors:  Biruk Bayleyegn; Tiruneh Adane; Solomon Getawa; Melak Aynalem; Zemen Demelash Kifle
Journal:  J Clin Lab Anal       Date:  2022-06-19       Impact factor: 3.124

3.  Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IB-IIA cervical cancer.

Authors:  Qiang An; Wei Liu; Yujia Yang; Bing Yang
Journal:  BMC Cancer       Date:  2020-07-25       Impact factor: 4.430

4.  Prognostic value of preoperative plasma fibrinogen levels in resected stage I non-small cell lung cancer.

Authors:  Suguru Mitsui; Yugo Tanaka; Takefumi Doi; Daisuke Hokka; Yoshimasa Maniwa
Journal:  Thorac Cancer       Date:  2022-04-12       Impact factor: 3.223

5.  Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy.

Authors:  Chengliang Yuan; Meifang Huang; Huilin Wang; Wei Jiang; Cuiyun Su; Shaozhang Zhou
Journal:  Cancer Manag Res       Date:  2022-01-26       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.